Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 28, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, March 27, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Maury Raycroft Initiated (ARWR) at Strong Buy and Held Target at $10 on, Mar 27th, 2018
Maury Raycroft of Jefferies, Initiated "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy and Held Target at $10 on, Mar 27th, 2018.
Maury has made no other calls on ARWR in the last 4 months.
There are 3 other peers that have a rating on ARWR. Out of the 3 peers that are also analyzing ARWR, 2 agree with Maury's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Elemer Piros of "Cantor Fitzgerald" Maintained at Hold with Increased Target to $5 on, Monday, February 12th, 2018
- Madhu Kumar of "B. Riley Securities" Maintained at Hold with Increased Target to $4 on, Monday, February 12th, 2018
This is the rating of the analyst that currently disagrees with Maury
- Edward Tenthoff of "Piper Sandler" Upgraded from Hold to Buy on, Monday, November 27th, 2017
